{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:08:24Z","timestamp":1767154104338,"version":"build-2238731810"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-022-00686-6","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T03:02:59Z","timestamp":1654570979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ATM germline variants in a young adult with chronic lymphocytic leukemia: 8\u2009years of genomic evolution"],"prefix":"10.1038","volume":"12","author":[{"given":"Romina","family":"Royo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-8386","authenticated-orcid":false,"given":"Laura","family":"Magnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ruiz-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Ll.","family":"Gelp\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3276-1889","authenticated-orcid":false,"given":"Holger","family":"Heyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7818-7595","authenticated-orcid":false,"given":"Malcom A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9525-1483","authenticated-orcid":false,"given":"Xose S.","family":"Puente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-9440","authenticated-orcid":false,"given":"Ferran","family":"Nadeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-9793","authenticated-orcid":false,"given":"El\u00edas","family":"Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"686_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bjh.17498","volume":"194","author":"HJ Cherng","year":"2021","unstructured":"Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, et al. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol. 2021;194:61\u201368.","journal-title":"Br J Haematol"},{"key":"686_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3324\/haematol.2008.003632","volume":"94","author":"LR Goldin","year":"2009","unstructured":"Goldin LR, Bjorkholm M, Kristinsson SY, Turesson I, Landgren O. Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin\u2019s lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica. 2009;94:647\u201353.","journal-title":"Haematologica."},{"key":"686_CR3","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/pbc.24884","volume":"61","author":"M Luskin","year":"2014","unstructured":"Luskin M, Wertheim G, Morrissette J, Daber R, Biegel J, Wilmoth D, et al. CLL\/SLL diagnosed in an adolescent. Pediatr Blood Cancer. 2014;61:1107\u201310.","journal-title":"Pediatr Blood Cancer"},{"key":"686_CR4","doi-asserted-by":"publisher","first-page":"S280","DOI":"10.1016\/j.clml.2019.07.216","volume":"19","author":"S Nassereddine","year":"2019","unstructured":"Nassereddine S, Dunleavy K. A case of chronic lymphocytic leukemia in an AYA patient. Clin Lymphoma Myeloma Leuk. 2019;19:S280.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"686_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente XS, Be\u00e0 S, Vald\u00e9s-Mas R, Villamor N, Guti\u00e9rrez-Abril J, Mart\u00edn-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526:519\u201324.","journal-title":"Nature."},{"key":"686_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3324\/haematol.2011.048827","volume":"97","author":"A Skowronska","year":"2012","unstructured":"Skowronska A, Austen B, Powell JE, Weston V, Oscier DG, Dyer MJS, et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica. 2012;97:142\u20136.","journal-title":"Haematologica."},{"key":"686_CR7","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/bjc.2011.266","volume":"105","author":"A Reiman","year":"2011","unstructured":"Reiman A, Srinivasan V, Barone G, Last JI, Wootton LL, Davies EG, et al. Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer. 2011;105:586\u201391.","journal-title":"Br J Cancer"},{"key":"686_CR8","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/leu.2017.201","volume":"31","author":"G Tiao","year":"2017","unstructured":"Tiao G, Improgo MR, Kasar S, Poh W, Kamburov A, Landau DA, et al. Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia. 2017;31:2244\u20137.","journal-title":"Leukemia."},{"key":"686_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1182\/blood.V100.2.603","volume":"100","author":"MR Yuille","year":"2002","unstructured":"Yuille MR, Condie A, Hudson CD, Bradshaw PS, Stone EM, Matutes E, et al. ATM mutations are rare in familial chronic lymphocytic leukemia. Blood. 2002;100:603\u20139.","journal-title":"Blood."},{"key":"686_CR10","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/humu.21034","volume":"30","author":"G Barone","year":"2009","unstructured":"Barone G, Groom A, Reiman A, Srinivasan V, Byrd PJ, Taylor AMR. Modeling ATM mutant proteins from missense changes confirms retained kinase activity. Hum Mutat. 2009;30:1222\u201330.","journal-title":"Hum Mutat"},{"key":"686_CR11","doi-asserted-by":"publisher","first-page":"30133","DOI":"10.1074\/jbc.M103160200","volume":"276","author":"GS Stewart","year":"2001","unstructured":"Stewart GS, Last JIK, Stankovic T, Haites N, Kidd AMJ, Byrd PJ, et al. Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T\u2192G mutations, showing a less severe phenotype. J Biol Chem. 2001;276:30133\u201341.","journal-title":"J Biol Chem"},{"key":"686_CR12","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1038\/bcj.2015.50","volume":"5","author":"IV Kostopoulos","year":"2015","unstructured":"Kostopoulos IV, Tsakiridou AA, Pavlidis D, Megalakaki A, Papadhimitriou SI. Familial chronic lymphocytic leukemia in two siblings with ATM\/13q14 deletion and a similar pattern of clonal evolution. Blood Cancer J. 2015;5:e322\u2013e322.","journal-title":"Blood Cancer J"},{"key":"686_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccell.2018.12.013","volume":"35","author":"S Yin","year":"2019","unstructured":"Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, et al. A murine model of chronic lymphocytic leukemia based on B cell-restricted expression of Sf3b1 mutation and Atm deletion. Cancer Cell. 2019;35:283\u2013296.e5.","journal-title":"Cancer Cell"},{"key":"686_CR14","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","volume":"123","author":"S Stilgenbauer","year":"2014","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, D\u00f6hner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247\u201354.","journal-title":"Blood."},{"key":"686_CR15","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.V128.22.2042.2042","volume":"128","author":"TJ Kipps","year":"2016","unstructured":"Kipps TJ, Hillmen P, Demirkan F, Grosicki S, Coutre SE, Barrientos JC, et al. 11q deletion (del11q) is not a prognostic factor for adverse outcomes for patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) treated with ibrutinib: pooled data from 3 randomized phase 3 studies. Blood. 2016;128:2042\u20132042.","journal-title":"Blood."}],"updated-by":[{"DOI":"10.1038\/s41408-022-00762-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00686-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00686-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00686-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T14:25:20Z","timestamp":1670595920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00686-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00686-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"11 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Unnecessary texts have been removed.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-022-00762-x","URL":"https:\/\/doi.org\/10.1038\/s41408-022-00762-x","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HH is co-founder of Omniscope and consultant to MiRXES. XSP is co-founder of and holds an equity stake in DREAMgenics. FN has received honoraria from Janssen for speaking at educational activities. EC has been a consultant for Takeda, NanoString, AbbVie, and Illumina; has received honoraria from Janssen, EUSPharma, and Roche for speaking at educational activities; and is an inventor on a Lymphoma and Leukemia Molecular Profiling Project patent \u201cMethod for subtyping lymphoma subtypes by means of expression profiling\u201d (PCT\/US2014\/64161) not related to this project. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}